Immunocore Holdings plc - ADR

+1.02 (+5.38%)

Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4

Published: 12/06/2021 13:01 GMT
Immunocore Holdings plc - ADR (IMCR) - Immunocore Announces Initial Phase 1 Data of Immtac® Candidate Imc-c103c Targeting Mage-a4.
Immunocore Holdings Plc - Clinical Activity With Confirmed Durable Responses in Ovarian Cancer and a Confirmed Durable Response in Hnscc.
Immunocore Holdings Plc - Biomarkers of T Cell Activation Consistent and Robust at Doses ≥ 90 Micrograms.
Immunocore Holdings Plc - First Expansion in High Grade Serous Ovarian Cancer Initiated.
Immunocore Holdings Plc - Imc-c103c Demonstrated a Manageable Safety Profile.